Grifols signs $90.7m respiratory deal with Aradigm

Grifols has signed a worldwide licensing agreement worth up to $90.7m to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

Grifols has signed a worldwide licensing agreement worth up to $90.7m to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

Plasma derivatives producer Grifols told Scrip that the deal is a "perfect fit with our current pulmonary business led by...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category